Jasmin Bahlo

Jasmin Bahlo

UNVERIFIED PROFILE

Are you Jasmin Bahlo?   Register this Author

Register author
Jasmin Bahlo

Jasmin Bahlo

Publications by authors named "Jasmin Bahlo"

Are you Jasmin Bahlo?   Register this Author

45Publications

1710Reads

28Profile Views

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.

Cell 2019 Jul 4;178(3):699-713.e19. Epub 2019 Jul 4.

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2019.06.011DOI Listing
July 2019

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

N Engl J Med 2019 06 4;380(23):2225-2236. Epub 2019 Jun 4.

From Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne (K.F., O.A.-S., J.B., A.-M.F., S. Robrecht, B.E., K.-A.K., M.H.), the Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital (V.G.), CECAD (Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases) (M.H.), Center for Molecular Medicine Cologne (M.H.), Cologne, Department III of Internal Medicine, University Hospital Rostock, Rostock (S.B.), Department III of Internal Medicine, Ulm University, Ulm (E.T., S.S.), the Departments of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases, and Tropical Medicine, Klinikum Schwabing, Munich (C.-M.W.), Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel (M.R.), and the Department of Hematology, Oncology, and Rheumatology, Saarland University Medical School, Homburg (S.S.) - all in Germany; Roche Products, Welwyn Garden City, United Kingdom (M.T., M.D., S.W., K.H.); Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod, Russia (O.S.); the Division of Onco-Hematology, Santa Maria Terni Hospital, University of Perugia, Perugia, Italy (A.M.L.); the Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.P.-I.); the Haematology Department, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (S.O.); First Internal Department, Multiprofile Hospital for Active Treatment Hristo Botev, Vratsa, Bulgaria (L.S.); the Hematology Department, Clinique Victor Hugo, Le Mans, France (K.L.D.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (L.M.F.); the Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen (C.U.N.); Wellington Blood and Cancer Centre, Capital and Coast District Health Board, and Malaghan Institute of Medical Research, Wellington, New Zealand (R.W.); Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (S. Robinson); Moores Cancer Center, University of California San Diego, San Diego (T.J.K.), and Genentech, South San Francisco (M.M.) - both in California; AbbVie, North Chicago, IL (R.H.); and the Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, the Netherlands (A.W.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1815281
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1815281DOI Listing
June 2019

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.

Leukemia 2019 05 19;33(5):1161-1172. Epub 2018 Dec 19.

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, CECAD Cluster of Excellence at the University of Cologne, Clinical Research Unit (KFO) 286, German CLL Study Group, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0313-8DOI Listing
May 2019

The Treatment of Chronic Lymphatic Leukemia.

Dtsch Arztebl Int 2019 01;116(4):41-46

Department of Internal Medicine I - Oncology, Hematology, Clinical Infectiology, Clinical Immunology, Hemostaseology, Internal Intensive Care; University Hospital Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3238/arztebl.2019.0041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415618PMC
January 2019

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.

Br J Haematol 2018 12 21;183(5):727-735. Epub 2018 Nov 21.

Department I of Internal Medicine and Centre of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15604DOI Listing
December 2018

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.

Future Oncol 2018 Mar 21;14(6):499-513. Epub 2018 Feb 21.

Department I of Internal Medicine & Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0442DOI Listing
March 2018

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

Eur J Haematol 2017 Mar 1;98(3):254-262. Epub 2016 Dec 1.

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study group, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12825DOI Listing
March 2017

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.

Leuk Lymphoma 2017 02 29;58(2):399-407. Epub 2016 Jun 29.

a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1190966DOI Listing
February 2017

Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective.

Eur J Haematol 2017 Feb 1;98(2):169-176. Epub 2016 Nov 1.

Department I of Internal Medicine, Center for Integrated Oncology Cologne, University Hospital of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12817DOI Listing
February 2017

Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group.

Leuk Lymphoma 2016 13;57(4):789-96. Epub 2015 Oct 13.

a German CLL Study Group, Department I of Internal Medicine , Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne , Cologne , Germany .

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2015.10
Publisher Site
http://dx.doi.org/10.3109/10428194.2015.1091933DOI Listing
December 2016

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

J Clin Oncol 2016 11;34(31):3758-3765

Gabor Kovacs, Sandra Robrecht, Anna Maria Fink, Jasmin Bahlo, Paula Cramer, Julia von Tresckow, Christian Maurer, Petra Langerbeins, Kirsten Fischer, Michael Hallek, and Barbara Eichhorst, University of Cologne and Center of Integrated Oncology Cologne/Bonn, Cologne; Matthias Ritgen, Michael Kneba, and Sebastian Böttcher, University of Schleswig-Holstein, Lubeck; Hartmut Döhner and Stephan Stilgenbauer, University of Ulm, Ulm; Wolfram Klapper, University of Kiel, Kiel; Clemens-Martin Wendtner, Klinikum Schwabing, Munich, Germany; and Günter Fingerle-Rowson, F. Hoffmann La-Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1305DOI Listing
November 2016

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.

Oncoimmunology 2016 Jun 22;5(6):e1150399. Epub 2016 Apr 22.

1st Department of Internal Medicine and Center for Integrated Oncology CIO Köln/Bonn, University Hospital of Cologne, Cologne, Germany; German Center for Infection Research (DZIF), Partner site Bonn-Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1150399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938364PMC
June 2016

The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.

Future Oncol 2015 ;11(13):1895-903

Department I of Internal Medicine, Center of Integrated Oncology (CIO), & CECAD - Cluster of Excellence 'Cellular Stress Responses in Aging-Associated Diseases,' University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.95DOI Listing
April 2016

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Blood 2016 Jan 20;127(2):208-15. Epub 2015 Oct 20.

Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany; Cluster of Excellence Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-06-651125DOI Listing
January 2016

Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual.

Leuk Res 2014 Mar 1;38(3):284-5. Epub 2013 Dec 1.

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.11.015DOI Listing
March 2014